首页|利拉鲁肽与达格列净联合二甲双胍治疗新诊断超重/肥胖2型糖尿病患者的效果

利拉鲁肽与达格列净联合二甲双胍治疗新诊断超重/肥胖2型糖尿病患者的效果

扫码查看
目的 探讨利拉鲁肽与达格列净联合二甲双胍治疗新诊断超重/肥胖 2 型糖尿病(T2DM)患者的效果。方法 选取 2022 年 1 月至 2023 年 6 月河池市人民医院收治的 127 例T2DM患者为研究对象,根据治疗方案不同分为利拉鲁肽组(n=62)与达格列净组(n=65)。利拉鲁肽组给予利拉鲁肽联合二甲双胍治疗,达格列净组给予达格列净联合二甲双胍治疗。比较两组腰围(WC)、体重指数(BMI)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、糖化血红蛋白(HbA1C)、总胆固醇(TC)、三酰甘油(TG)、血尿酸(SUA)、尿微量白蛋白/肌酐比值(UACR)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)及不良反应。结果 治疗后,两组WC、BMI、SBP及DBP较治疗前显著改善(P<0。05);利拉鲁肽组WC、BMI低于达格列净组(P<0。05),SBP及DBP高于达格列净组(P<0。05)。治疗后,两组FPG、HbA1C、TG、SUA、UACR及HDL-C比较差异无统计学意义(P>0。05),利拉鲁肽组TC及LDL-C水平低于达格列净组(P<0。05)。利拉鲁肽组恶心呕吐发生率高于达格列净组(P<0。05),酮症、泌尿生殖道感染发生率低于达格列净组(P<0。05)。结论 对于新诊断超重/肥胖T2DM患者,利拉鲁肽与达格列净联合二甲双胍治疗均可有效控制血糖,利拉鲁肽可降低WC、BMI,达格列净更有助于降低血压。利拉鲁肽易引起上消化道不良反应,达格列净诱发酮症、泌尿生殖道感染的风险更高。
Efficacy of Liraglutide and Dagliprazin combined with Metformin in Newly Diagnosed Overweight/obese Patients with Type 2 Diabetes Mellitus
Objective To explore the effect of liraglutide and dagliprazin combined with metformin in newly diagnosed overweight/obese patients with type 2 diabetes mellitus(T2DM).Methods A total of 127 T2DM patients admitted to the People's Hospital of Hechi City from January 2022 to June 2023 were selected as the study objects,and were divided into Liraglutide group(n=62)and Dagliaglizin group(n=65)according to different treatment plans.The liraglutide group was given liraglutide combined with metformin,and dagliprazin group was given dagliprazin combined with metformin.The waist circumference(WC),body mass index(BMI),systolic blood pressure(SBP),diastolic blood pressure(DBP),fasting blood glucose(FPG),glycosylated hemoglobin(HbA1C),total cholesterol(TC),triglyceride(TG),blood uric acid(SUA),urinary microalbumin/creatinine ratio(UACR),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)and adverse reactions were compared between two groups.Results After treatment,WC,BMI,SBP and DBP in both groups were significantly improved compared with those before treatment(P<0.05).WC and BMI in Liraglutide group were lower than those in Daglipzin group(P<0.05),SBP and DBP in liraglutide group were higher than those in Daglipzin group(P<0.05).After treatment,there were no significant differences in FPG,HbA1C,TG,SUA,UACR and HDL-C between the two groups(P>0.05),but the levels of TC and LDL-C in Liraglutide group were lower than those in dagliprazin group(P<0.05).The incidence of nausea and vomiting in Liraglutide group was higher than that in dagliprazin group(P<0.05),and the incidence of ketosis and urogenital tract infection was lower than that in Dagliprazin group(P<0.05).Conclusion For newly diagnosed overweight/obese T2DM patients,liraglutide and dagliprazin combined with metformin can effectively control blood glucose,liraglutide can reduce WC and BMI,and dagliprazin is more conducive to lowering blood pressure.Liraglutide was more likely to cause adverse reactions in the upper digestive tract,and dagliprazin was more likely to induce ketosis and urogenital tract infection.

Type 2 diabetes mellitusNewly diagnosedDagliprazinLiraglutideObese

徐丽玲、黄剑良

展开 >

河池市人民医院全科医疗科,广西河池 547000

2型糖尿病 新诊断 达格列净 利拉鲁肽 肥胖

广西壮族自治区卫生健康委员会自筹经费科研课题

Z20210319

2024

中国药物经济学
中国中医药研究促进会

中国药物经济学

影响因子:0.712
ISSN:1673-5846
年,卷(期):2024.19(6)